Skip to main content

REVIEW article

Front. Med.
Sec. Rheumatology
Volume 11 - 2024 | doi: 10.3389/fmed.2024.1385123

Natural Biomimetic Nano-system for Drug Delivery in the Treatment of Rheumatoid Arthritis: A Literature Review of the Last 5 Years Provisionally Accepted

Jingyuan Li1 Wei Li1  Liping Zhuang1*
  • 1The First People Hospital of Mudanjiang City, China

The final, formatted version of the article will be published soon.

Receive an email when it is updated
You just subscribed to receive the final version of the article

Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease characterized primarily by synovitis, leading to the destruction of articular cartilage and bone and ultimately resulting in joint deformity, loss of function, and a significant impact on patients' quality of life. Currently, a combination of anti-rheumatic drugs, hormonal drugs, and biologics is used to mitigate disease progression. However, conventional drug therapy has limited bioavailability, and long-term use often leads to drug resistance and toxic side effects. Therefore, exploring new therapeutic approaches for RA is of great clinical importance. Nanodrug delivery systems offer promising solutions to overcome the limitations of conventional drugs. Among them, liposomes, the first nanodrug delivery system to be approved for clinical application and still widely studied, demonstrate the ability to enhance therapeutic efficacy with fewer adverse effects through passive or active targeting mechanisms. In this review, we provide a review of the research progress on the targeting mechanisms of various natural biomimetic nano-delivery systems in RA therapy. Additionally, we predict the development trends and application prospects of these systems, offering new directions for precision treatment of RA.

Keywords: Rheumatoid arthritis, natural biomimetic, Nano-system, Drug delivery, Treatment

Received: 12 Feb 2024; Accepted: 16 Apr 2024.

Copyright: © 2024 Li, Li and Zhuang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Mx. Liping Zhuang, The First People Hospital of Mudanjiang City, Mudanjiang, China